FDA Acceptance of Supplemental NDA for MS CONTIN by KNOA PHARMA
The FDA has accepted a supplemental NDA for MS CONTIN, containing morphine sulfate, submitted by KNOA PHARMA.
Company
Pharmaceutical intelligence for KNOA PHARMA with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.